Semaglutide Costs & Access: Could $3 Doses Expand Weight Loss Treatment?
A widely used medication for obesity and diabetes, semaglutide – marketed as Wegovy for weight management and Ozempic for type 2 diabetes – could become significantly more affordable in the near future. New research suggests the drug could be manufactured for as little as $3 per monthly dose in its injectable form, potentially expanding access to millions globally.
The findings, currently available as a pre-print, come as patents on semaglutide are set to expire in several key countries, including Brazil, China, India, South Africa, Turkey, Mexico and Canada, starting on . This expiration will open the door for generic drug manufacturers to produce and distribute lower-cost versions of the medication. Researchers also identified approximately 150 countries where patents for semaglutide were never filed, particularly in Africa, further paving the way for broader availability.
Semaglutide’s potential impact is substantial. More than one billion people worldwide live with obesity, and rates are increasing, particularly in lower-income nations adopting more Westernized diets and lifestyles. The World Health Organization (WHO) designated semaglutide as an essential medicine in , recognizing its importance in addressing the global obesity epidemic. However, the high cost of the drug has been a significant barrier to access.
The research indicates that a pill formulation of semaglutide could be produced for around $16 per month. While more expensive than the injectable form, this offers a convenient alternative for patients who prefer oral medication. Dr. Andrew Hill of Liverpool University’s pharmacology department, one of the study’s authors, stated that these lower prices open the door to worldwide access to an essential medicine.
Currently, Wegovy and Ozempic are manufactured by Novo Nordisk. The potential for generic competition is expected to drive down prices and increase accessibility, particularly in countries where healthcare resources are limited. The impact could be transformative for individuals struggling with obesity and type 2 diabetes who previously could not afford treatment.
The affordability of semaglutide is particularly relevant given the rising prevalence of obesity and its associated health complications, including heart disease, stroke, type 2 diabetes, and certain types of cancer. Obesity places a significant strain on healthcare systems worldwide, and effective treatments are crucial for improving public health outcomes.
While the $3 price point refers to the cost of manufacturing the injectable form, the final price consumers pay will also depend on factors such as distribution costs, pharmacy markups, and insurance coverage. However, the research suggests a substantial reduction in cost is achievable, even after accounting for these additional expenses.
The availability of generic semaglutide is not without potential challenges. Ensuring the quality and safety of generic medications is paramount, and regulatory agencies will need to rigorously oversee the manufacturing process. Healthcare providers will need to be educated about the availability of lower-cost options and how to appropriately prescribe them.
The development of affordable semaglutide represents a significant step forward in the fight against obesity and diabetes. By increasing access to this essential medicine, it has the potential to improve the health and well-being of millions of people around the world. Further monitoring of pricing and access will be crucial to ensure that the benefits of generic competition are fully realized.
GoodRx is also responding to Novo Nordisk’s pricing for oral semaglutide by matching the price, further increasing options for patients. This move highlights the growing competition and focus on affordability within the semaglutide market.